文献速递临床试验与 GCP真实世界研究与卫生经济医学人工智能与信息学

计算机辅助X线筛查结核与HIV检测的成本效果随机试验

Computer-aided X-ray screening for tuberculosis and HIV testing among adults with cough in Malawi (the PROSPECT study): A randomised trial and cost-effectiveness analysis.
PubMed 文献 · PLoS Med · 2021-09-09

在马拉维因咳嗽就诊的成人中开展三臂随机试验,比较标准诊疗、HIV检测以及HIV检测联合数字胸片计算机辅助诊断(DCXR-CAD)筛查结核。DCXR-CAD联合HIV筛查提高了结核治疗及时性与完整性,并减少未诊断HIV,但增量成本较高。

要点

  • DCXR-CAD联合HIV筛查使结核治疗启动更快,中位时间由11天缩短至1天。
  • 该策略使同日启动结核治疗比例由0%提高至40.0%。
  • HIV筛查显著减少未诊断或未治疗HIV比例,联合组效果更明显。

核心结论

  • DCXR-CAD联合普遍HIV筛查显著提高了HIV和结核诊断的及时性与完整性。
  • 若推广实施,该策略有潜力快速高效改善结核和HIV的诊断与治疗。

研究设计与样本

  • 开放标签三臂随机试验,在马拉维急性初级诊疗机构纳入≥18岁因咳嗽就诊的成人,按1:1:1随机分组。
  • 三组分别为标准诊疗(SOC)、口服HIV检测并链接照护、HIV检测联合DCXR-CAD(高CAD4TBv5评分者行痰Xpert)筛查。
  • 共473、492、497例分别分配至SOC、HIV筛查和HIV-TB筛查组,按意向性治疗分析。
  • 成本效果分析采用卫生服务提供者视角。

主要发现

  • 56天时,SOC、HIV筛查和HIV-TB筛查组分别有5例(1.1%)、8例(1.6%)和15例(3.0%)启动结核治疗。
  • 至结核治疗的中位时间(IQR)分别为11(6.5至38)、6(1至22)和1(0至3)天,HIV-TB筛查组对比SOC的风险比为2.86(1.04至7.87)。
  • 同日启动结核治疗比例分别为0/5(0%)、1/8(12.5%)和6/15(40.0%),p=0.03。
  • HIV筛查将未诊断或未治疗HIV比例从SOC组的10例(2.7%)降至HIV筛查组的2例(0.5%)(RR:0.18,0.04至0.83),HIV-TB筛查组为1例(0.2%)(RR:0.09,0.01至0.71)。
  • 每名受试者增量成本分别为HIV筛查3.58美元和HIV-TB筛查19.92美元;在1200美元/质量调整生命年阈值下,成本效果概率分别为83.9%和0%。

关键数值与推荐

  • 高CAD4TBv5评分者行痰Xpert检查。
  • 主要结局为至结核治疗时间,次要结局包括同日结核治疗比例、第56天未诊断/未治疗细菌学确诊结核和未诊断/未治疗HIV。

临床怎么用

  • 对因咳嗽就诊的成人,可考虑HIV检测联合DCXR-CAD筛查以加快结核诊断和治疗启动。
  • 该策略可减少未诊断HIV,但需评估增量成本与当地支付意愿阈值。

局限性

  • 结核患病率低于预期。
  • 受试者随访时间较短,筛查的成本与生活质量获益可能需要更长时间观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Suboptimal tuberculosis (TB) diagnostics and HIV contribute to the high global burden of TB. We investigated costs and yield from systematic HIV-TB screening, including computer-aided digital chest X-ray (DCXR-CAD). METHODS AND FINDINGS: In this open, three-arm randomised trial, adults (≥18 years) with cough attending acute primary services in Malawi were randomised (1:1:1) to standard of care (SOC); oral HIV testing (HIV screening) and linkage to care; or HIV testing and linkage to care plus DCXR-CAD with sputum Xpert for high CAD4TBv5 scores (HIV-TB screening). Participants and study staff were not blinded to intervention allocation, but investigator blinding was maintained until final analysis. The primary outcome was time to TB treatment. Secondary outcomes included proportion with same-day TB treatment; prevalence of undiagnosed/untreated bacteriologically confirmed TB on day 56; and undiagnosed/untreated HIV. Analysis was done on an intention-to-treat basis. Cost-effectiveness analysis used a health-provider perspective. Between 15 November 2018 and 27 November 2019, 8,236 were screened for eligibility, with 473, 492, and 497 randomly allocated to SOC, HIV, and HIV-TB screening arms; 53 (11%), 52 (9%), and 47 (9%) were lost to follow-up, respectively. At 56 days, TB treatment had been started in 5 (1.1%) SOC, 8 (1.6%) HIV screening, and 15 (3.0%) HIV-TB screening participants. Median (IQR) time to TB treatment was 11 (6.5 to 38), 6 (1 to 22), and 1 (0 to 3) days (hazard ratio for HIV-TB versus SOC: 2.86, 1.04 to 7.87), with same-day treatment of 0/5 (0%) SOC, 1/8 (12.5%) HIV, and 6/15 (40.0%) HIV-TB screening arm TB patients (p = 0.03). At day 56, 2 SOC (0.5%), 4 HIV (1.0%), and 2 HIV-TB (0.5%) participants had undiagnosed microbiologically confirmed TB. HIV screening reduced the proportion with undiagnosed or untreated HIV from 10 (2.7%) in the SOC arm to 2 (0.5%) in the HIV screening arm (risk ratio [RR]: 0.18, 0.04 to 0.83), and 1 (0.2%) in the HIV-TB screening arm (RR: 0.09, 0.01 to 0.71). Incremental costs were US$3.58 and US$19.92 per participant screened for HIV and HIV-TB; the probability of cost-effectiveness at a US$1,200/quality-adjusted life year (QALY) threshold was 83.9% and 0%. Main limitations were the lower than anticipated prevalence of TB and short participant follow-up period; cost and quality of life benefits of this screening approach may accrue over a longer time horizon. CONCLUSIONS: DCXR-CAD with universal HIV screening significantly increased the timeliness and completeness of HIV and TB diagnosis. If implemented at scale, this has potential to rapidly and efficiently improve TB and HIV diagnosis and treatment. TRIAL REGISTRATION: clinicaltrials.gov NCT03519425.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. MacPherson P, Webb EL, Kamchedzera W, et al. Computer-aided X-ray screening for tuberculosis and HIV testing among adults with cough in Malawi (the PROSPECT study): A randomised trial and cost-effectiveness analysis. PLoS Med. 2021. PMID: 34499665. doi:10.1371/journal.pmed.1003752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。